A similar connection was reported by Fujimoto and collaborators: working on YMB-1 Her-positive BCA cells resistant to trastuzumab, they found that TMEM16A blockers sensibly suppressed cell viability, thus suggesting that sensitivity to HER2 addressed therapy, approved for treatment of metastatic breast and cancer therapy, can be modulated by the presence of TMEM16A [153]. This evidence concerns the gene ANO1 and medical procedure.